Dr. Zhou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
Vanderbilt University Medical CenterResidency, Internal Medicine, 2016 - 2019
Perelman School of Medicine at the University of PennsylvaniaClass of 2016
Certifications & Licensure
MO State Medical License 2019 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors Start of enrollment: 2024 Jun 30
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma.Jordan Phillipps, George Nassief, Renee Morecroft, Tolulope Adeyelu, Andrew Elliott
NPJ Precision Oncology. 2024-09-05 - 1 citationsPoly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification.George Nassief, Omar H Butt, Alice Y Zhou, George Ansstas
JAAD Case Reports. 2024-06-01 - 1 citationsInduced CD8α identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation.Celia C Cubitt, Pamela Wong, Hannah K Dorando, Jennifer A Foltz, Jennifer Tran
The Journal of Clinical Investigation. 2024-05-28
Press Mentions
Neurodegenerative Biomarker May Predict CAR T-cell Therapy-Related NeurotoxicityJanuary 26th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
